<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37061279</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Relative CTLA-4, PTPN-22, and interleukin 37 mRNA expressions in patients with lupus nephritis.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>187</EndPage><MedlinePgn>180-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reumae.2023.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5743(23)00033-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by T-cell immune-dysregulation and loss of tolerance to self-antigens. CTLA-4 and PTPN-22 are involved in the inhibition of T-lymphocytes activation. IL-37 is an anti-inflammatory cytokine that suppresses innate immunity. The relative expression of CTLA-4, IL-37 and PTPN-22 were evaluated as negative regulators of immune response in SLE patients, lupus nephritis (LN) and disease activity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Real-Time PCR was performed to determine relative CTLA-4, IL-37, and PTPN-22 mRNA expressions in fifty-eight SLE patients, who were divided into two groups: 29 SLE patients without nephritis and 29 patients with LN, versus fifty controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a significantly high-expression of CTLA-4 and IL-37 genes in SLE patients compared to controls (p=0.005; 0.018 respectively). There was no difference in relative PTPN-22 mRNA expression between the SLE patients and controls. Relative CTLA-4 mRNA expression decreased in LN patients (p=0.044), however, relative IL-37 mRNA over-expressed in LN patients (p=0.001) compared to those without LN. There was a significant over-expression of relative IL-37 andPTPN-22 mRNA in active SLE patients. But, there was a non-significant difference in CTLA-4 expression with disease activity. Regression analysis revealed patients with relative IL-37 mRNA over-expression had two times more to develop lupus nephritis (OR=1.906, 95% CI=1.218-2.983, p=0.005).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Relative IL-37mRNA expression was elevated in SLE patients and associated with renal involvement and disease activity. It could be considered as a new promising predicting tool for LN. Relative PTPN-22 mRNA expression was correlated with disease activity only in SLE patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>A Moneim</LastName><ForeName>Nermeen Hassan</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosny</LastName><ForeName>Marwa Mohamed</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt; Oncology Diagnostic Unit Lab, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omar</LastName><ForeName>Hanan Hassan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. Electronic address: hananhassan1978@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelnaby</LastName><ForeName>Mai Mohamed</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fouad</LastName><ForeName>Marwa Mohamed</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abd El-Waheed</LastName><ForeName>Waleed Omar</ForeName><Initials>WO</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmedany</LastName><ForeName>Samah Hamdy</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaki</LastName><ForeName>Heba Mohamed</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007378">Interleukins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508587">IL37 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CTLA-4</Keyword><Keyword MajorTopicYN="N">IL-37</Keyword><Keyword MajorTopicYN="N">Lupus eritematoso sist&#xe9;mico</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Nefritis l&#xfa;pica</Keyword><Keyword MajorTopicYN="N">PTPN-22</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37061279</ArticleId><ArticleId IdType="doi">10.1016/j.reumae.2023.03.004</ArticleId><ArticleId IdType="pii">S2173-5743(23)00033-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>